The development of point mutation detection techniques has promoted the analysis of biopsy specimens and enables the analysis of plasma- and serum-containing ctDNA, allowing for early and accurate detection of KRAS mutations in CRC patients. This evidence concerns the gene KRAS and colorectal carcinoma.